Innate Pharma has finally called time on an NK cell engager in phase 1/2 development as part of an ongoing fine-tuning of the ...

Dose escalation for NKX019 advanced to 4 billion cells per dose on days 0, 3 and 7 for a total of 12 billion cells per cycleInitial clinical data ...

A technique that transforms immune cells into cancer-seeking bloodhounds may overcome a roadblock that has hampered ...

Shares of ImmunityBio IBRX rose more than 7% on Friday after the company announced that it completed two manufacturing ...

Natural killer cells, also referred to as NK cells, play several major roles in the body's defense against cancers like renal cell carcinoma. Natural killer cells, also referred to as NK cells, play ...

ImmunityBio Inc. (NASDAQ:IBRX) is one of the 10 Must-Watch Stocks Right Now. ImmunityBio surged by 7.29 percent on Friday to ...

GC Cell announced on the 27th that it presented interim Phase 1 clinical trial results for its allogeneic umbilical cord ...

These findings suggest that KIR2DS2-positive (KIR2DS2+) natural killer (NK) cells could be an attractive therapeutic target for in vivo strategies, although enhanced effector function is lost during ...

Findings provide a foundation for further exploration of natural killer cells for the development of future treatments and therapies for a range of lung diseases, including chronic obstructive ...

In a study that further corroborated these observations, scientists found that cyclic fasting in mice improved their antitumor responses mediated by natural killer (NK) cells. 4 The results, published ...

French biotech Innate Pharma is recruiting natural-born killers to target B cell non-Hodgkin lymphoma (B-NHL). The company’s tetraspecific antibody controlled tumors and improved survival in mice and ...